Coverage Gap Discount
A manufacturer discount of 70% on brand-name drugs while a Part D beneficiary is in the coverage gap phase; counts toward the beneficiary's true out-of-pocket (TrOOP) spending.
The coverage gap discount program requires pharmaceutical manufacturers to pay 70% of the cost of their brand-name drugs when Part D beneficiaries are in the coverage gap. The remaining 30% is split between the plan (5%) and the beneficiary (25%). Critically, the full 95% (70% manufacturer discount + 25% beneficiary payment) counts toward the beneficiary's True Out-of-Pocket (TrOOP) spending threshold — accelerating progress through the gap toward catastrophic coverage.
This discount mechanism was introduced in the ACA as an incentive for manufacturers to participate in Medicare Part D. Without counting the manufacturer discount toward TrOOP, beneficiaries taking expensive brand-name drugs would take far longer (or never) reach catastrophic coverage, where their cost-sharing drops significantly.
For the 2025 benefit year, the donut hole effectively ends and the $2,000 OOP cap applies. The manufacturer discount continues in modified form, but its role in TrOOP calculation changes under the new structure. Beneficiaries with multiple expensive brand-name drugs in 2024 should model their spending carefully to understand how quickly they will progress through coverage phases.
Real-World Example
A Part D enrollee in 2024 paid $2,000 out-of-pocket for a $8,000 specialty drug while in the coverage gap — but the full $7,600 (70% manufacturer discount + her 25% copay) counted toward TrOOP, pushing her into catastrophic coverage much faster than the actual cash she paid.